PMCB Strangle Strategy
PMCB (PharmaCyte Biotech, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
PMCB (PharmaCyte Biotech, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $5.5M, a beta of 0.46 versus the broader market, a 52-week range of 0.63-1.51, average daily share volume of 142K, a public-listing history dating back to 2013, approximately 2 full-time employees. These structural characteristics shape how PMCB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.46 indicates PMCB has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on PMCB?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current PMCB snapshot
As of May 15, 2026, spot at $0.82, ATM IV 20.60%, IV rank 0.64%, expected move 5.91%. The strangle on PMCB below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on PMCB specifically: PMCB IV at 20.60% is on the cheap side of its 1-year range, which favors premium-buying structures like a PMCB strangle, with a market-implied 1-standard-deviation move of approximately 5.91% (roughly $0.05 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated PMCB expiries trade a higher absolute premium for lower per-day decay. Position sizing on PMCB should anchor to the underlying notional of $0.82 per share and to the trader's directional view on PMCB stock.
PMCB strangle setup
The PMCB strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With PMCB near $0.82, the first option leg uses a $0.86 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed PMCB chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 PMCB shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $0.86 | N/A |
| Buy 1 | Put | $0.78 | N/A |
PMCB strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
PMCB strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on PMCB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on PMCB
Strangles on PMCB are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the PMCB chain.
PMCB thesis for this strangle
The market-implied 1-standard-deviation range for PMCB extends from approximately $0.77 on the downside to $0.87 on the upside. A PMCB long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current PMCB IV rank near 0.64% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on PMCB at 20.60%. As a Healthcare name, PMCB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to PMCB-specific events.
PMCB strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. PMCB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move PMCB alongside the broader basket even when PMCB-specific fundamentals are unchanged. Always rebuild the position from current PMCB chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on PMCB?
- A strangle on PMCB is the strangle strategy applied to PMCB (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With PMCB stock trading near $0.82, the strikes shown on this page are snapped to the nearest listed PMCB chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are PMCB strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the PMCB strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 20.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a PMCB strangle?
- The breakeven for the PMCB strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current PMCB market-implied 1-standard-deviation expected move is approximately 5.91%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on PMCB?
- Strangles on PMCB are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the PMCB chain.
- How does current PMCB implied volatility affect this strangle?
- PMCB ATM IV is at 20.60% with IV rank near 0.64%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.